Erik J. Tillman
机构：Spero Therapeutics (United States) · ORCID：0000-0003-3599-0297
发表论文 29 篇 · 总被引 2181 次 · h-index 17
代表论文
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021 · Nature Medicine · 被引 357)
- Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023 · The Lancet. Gastroenterology & hepatology · 被引 256)
- FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases (2020 · Frontiers in Endocrinology · 被引 212)
- Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters (2013 · Proceedings of the National Academy of Sciences · 被引 194)
- AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients (2020 · Cell Reports Medicine · 被引 132)
- De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling (2014 · PLoS Biology · 被引 114)